{"id":251142,"date":"2025-02-17T00:00:00","date_gmt":"2025-02-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidcg0042-biopharma-muscular-dystrophy-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:26:59","modified_gmt":"2026-03-31T10:26:59","slug":"epidcg0042-biopharma-muscular-dystrophy-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0042-biopharma-muscular-dystrophy-epidemiology-mature-markets\/","title":{"rendered":"Muscular Dystrophy &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of nine types of muscular dystrophy: Duchenne muscular dystrophy (<abbr title=\"Duchenne muscular dystrophy\">DMD<\/abbr>), Becker muscular dystrophy (<abbr title=\"Becker muscular dystrophy\">BMD<\/abbr>), myotonic dystrophy (<abbr title=\"myotonic dystrophy\">DM<\/abbr>), congenital muscular dystrophy (<abbr title=\"congenital muscular dystrophy\">CMD<\/abbr>),<sup>1<\/sup> distal muscular dystrophy (<abbr title=\"distal muscular dystrophy\">DD<\/abbr>),<sup>1<\/sup> Emery-Dreifuss muscular dystrophy (<abbr title=\"Emery-Dreifuss muscular dystrophy\">EDMD<\/abbr>),<sup>1<\/sup> facioscapulohumeral muscular dystrophy (<abbr title=\"facioscapulohumeral muscular dystrophy\">FSHD<\/abbr>), limb-girdle muscular dystrophy (<abbr title=\"limb-girdle muscular dystrophy\">LGMD<\/abbr>),<sup>1<\/sup> and oculopharyngeal muscular dystrophy (<abbr title=\"oculopharyngeal muscular dystrophy\">OPMD<\/abbr>),<sup>1<\/sup> as well as the diagnosed incidence of <abbr title=\"Duchenne muscular dystrophy\">DMD<\/abbr>, together with annualized case counts projected to the national populations.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s muscular dystrophy forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with muscular dystrophy per year?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of muscular dystrophy over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <span class=\"abbreviation-guard\">MS<\/span> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In addition to the above-mentioned total number of diagnosed prevalent and incident cases for each forecast year, Clarivate Epidemiology provides 20 years of forecast data for the following subpopulations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed prevalence of <abbr title=\"Duchenne muscular dystrophy\">DMD<\/abbr> by ambulatory status.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"Duchenne muscular dystrophy\">DMD<\/abbr> by exon-skipping-amenable mutation status.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"Duchenne muscular dystrophy\">DMD<\/abbr> with nonsense mutations.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"Duchenne muscular dystrophy\">DMD<\/abbr> with cardiomyopathy.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"myotonic dystrophy\">DM<\/abbr> by subtype.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"myotonic dystrophy type 1\">DM1<\/abbr> by age of onset.<\/li>\n<li>Diagnosed prevalence of <abbr title=\"congenital muscular dystrophy\">CMD<\/abbr> by subtype.<sup>1<\/sup><\/li>\n<li>Diagnosed prevalence of <abbr title=\"limb-girdle muscular dystrophy\">LGMD<\/abbr> by subtype.<sup>1<\/sup><\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n<p>1. Excluding Japan because of data unavailability.<\/p>\n","protected":false},"template":"","class_list":["post-251142","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-muscular-dystrophy","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251142","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251142\/revisions"}],"predecessor-version":[{"id":448726,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251142\/revisions\/448726"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251142"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}